PaxMedica Announces Efficacy of PAX-101 (IV suramin) in Reducing Core Symptoms of Autism Spectrum Disorder
PaxMedica announced positive results from a phase 2 dose-ranging clinical trial evaluating PAX-124890-=101 demonstrated sustained improvements over placebo in the […]